Graham Capital Management’s Novo Nordisk NVO Stock Holding History

Graham Capital Management’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-3,518	Closed	-$243K	–	1526
2025 Q2	$243K	Sell	3,518 -12,782	-78%	-$869K	﹤0.01%	1062
2025 Q1	$1.13M	Buy	+16,300	New	+$1.35M	0.02%	509
2024 Q4	–	Sell	-14,170	Closed	-$1.69M	–	1407
2024 Q3	$1.69M	Buy	+14,170	New	+$1.89M	0.03%	328
2024 Q1	–	Sell	-12,179	Closed	-$1.26M	–	1230
2023 Q4	$1.26M	Buy	+12,179	New	+$1.2M	0.03%	324
2014 Q4	–	Sell	-40,000	Closed	-$952K	–	166
2014 Q3	$952K	Buy	40,000 +29,000	+264%	+$667K	0.04%	124
2014 Q2	$254K	Buy	+11,000	New	+$243K	0.01%	148

Other funds holding NVO

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Graham Capital Management's NVO Position: Q3 2025 in Review

Graham Capital Management sold out of Novo Nordisk (NVO) in Q3 2025, closing a stake of 3,518 shares — an estimated $243K sold.

Graham Capital Management first reported a position in NVO in Q2 2014 and held it in 6 quarters. The position peaked at $1.69M in Q3 2024. 1,395 funds tracked by Wall St. Rank hold NVO as of Q3 2025.

Graham Capital Management reported no remaining Novo Nordisk position as of Q3 2025 after selling out during the quarter.
Graham Capital Management sold 3,518 Novo Nordisk shares in Q3 2025, an estimated $243K.
Graham Capital Management first reported a position in Novo Nordisk in Q2 2014 and held it in 6 quarters.
Graham Capital Management's Novo Nordisk position peaked at $1.69M in Q3 2024.
1,395 funds tracked by Wall St. Rank held Novo Nordisk as of Q3 2025.

Based on Graham Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.